Session Information

WCLC 2017

18th World Conference on Lung Cancer

Conference Program for the 18th World Conference on Lung Cancer in Yokohama, Japan

Download PDF of the Conference Program: Click Here.
Onsite Conference Program Addendum (17/10/2017): Click Here.
Download PDF of the Abstract Book: Click Here.
Financial Disclosure Summary (PDF): Click Here.
Presentation Date(s):
- Oct 15 - 18, 2017
- Total Presentations: 2295
Register to Attend WCLC Return to WCLC 2017 Website Switch to Virtual Meeting
Enter Virtual Meeting Access Code

All Days Saturday
October 14 Sat
Oct 14 Sunday
October 15 Sun
Oct 15 Monday
October 16 Mon
Oct 16 Tuesday
October 17 Tue
Oct 17 Wednesday
October 18 Wed
Oct 18

Filter Results:

Show Only CME Accredited Sessions

18971

+
P1.02 - Biology/Pathology
- 09:30 - 16:00
- 10/16/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Biology/Pathology
- 22487
  
  +
  
  P1.02-003 - Prevention of Adriamycin-induced Cardiac Damage by NAD-ModulationPrevention of Adriamycin-induced Cardiac Damage by NAD-Modulation
  
  09:30 - 09:30 | Presenter: Sei-Hoon Yang | Author(s): K. Kwon, D. Khadka, G. Oh, H. Kim, S. Lee, A. Pandit, S. Lee, H. So
  Abstract
  
  Loading...
- 22508
  
  +
  
  P1.02-024 - Correlation of Maximal Tumor Diameter between Pathology Specimen and CT in Nonsmall Cell Lung Cancer: A Pilot Study
  
  09:30 - 09:30 | Presenter: Heae Surng Park | Author(s): C.H. Park, S. Lee, T.H. Kim
  Abstract
  
  Loading...
20154

+
P1.05 - Early Stage NSCLC
- 09:30 - 16:00
- 10/16/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Early Stage NSCLC
- 22636
  
  +
  
  P1.05-014 - Efficacy of Adjuvant Chemotherapy for Completely Resected Stage IB Non-Small Cell Lung Cancer
  
  09:30 - 09:30 | Presenter: S.H. Kim | Author(s): Min Kwang Byun, H.J. Park, Heae Surng Park, H. Jeung, J.Y. Cho, S.S. Lee
  Abstract
  
  Loading...
20157

+
P1.08 - Locally Advanced NSCLC
- 09:30 - 16:00
- 10/16/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Locally Advanced NSCLC
- 22716
  
  +
  
  P1.08-004 - Adjuvant Chemoradiotherapy vs. Chemotherapy for Completely Resected Unsuspected N2-Positive Non-Small Cell Lung Cancer
  
  09:30 - 09:30 | Presenter: Jong-Mu Sun | Author(s): Hong Kwan Kim, S. Lee, Yong Chan Ahn, Jhingook Kim, Myung-Ju Ahn, J.I. Zo, Y.M. Shim, Keunchil Park
  Abstract
  
  Loading...
20162

+
P1.13 - Radiology/Staging/Screening
- 09:30 - 16:00
- 10/16/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Radiology/Staging/Screening
- 22762
  
  +
  
  P1.13-006 - The Value of F-18 FDG PET/CT-guided EBUS-TBNA in Nodal Staging of NSCLC.
  
  09:30 - 09:30 | Presenter: Sung Yong Lee | Author(s): S. Lee, D. Lee, K.H. Jung, S. Kim
  Abstract
  
  Loading...
20118

+
OA 03 - Mediastinal and Esophageal Tumor: Insight and New Treatment
- 11:00 - 12:30
- 10/16/2017
- Location: Room 311 + 312
- Type: Oral
- Track: Thymic Malignancies/Esophageal Cancer/Other Thoracic Malignancies
- Moderators:M. Chida, Jhingook Kim
- 22950
  
  +
  
  OA 03.04 - A Phase II Study of Pembrolizumab for Patients with Refractory or Relapsed Thymic Epithelial Tumor
  
  11:30 - 11:40 | Presenter: Jinhyun Cho | Author(s): K.H. Yoo, Hansang Lee, H.K. Kim, Y. Kim, J.H. Cho, S.W. Lim, Song Ee Park, Jong-Mu Sun, S. Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn
  Abstract
  
  Loading...
20121

+
OA 05 - Next Generation TKI
- 15:45 - 17:30
- 10/16/2017
- Location: Room 301 + 302
- Type: Oral
- Track: Advanced NSCLC
- Moderators:James Chih-Hsin Yang, Fiona Blackhall
- 23044
  
  +
  
  OA 05.02 - Osimertinib vs SoC EGFR-TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC (FLAURA): Plasma ctDNA Analysis
  
  15:55 - 16:05 | Presenter: Jhanelle Elaine Gray | Author(s): Isamu Okamoto, V. Sriuranpong, Johan F. Vansteenkiste, F. Imamura, J.S. Lee, Y. Pang, M. Cobo, K. Kasahara, R. Hodge, Brian B Lentrichia, S. Dearden, Suresh S Ramalingam
  Abstract
  
  Loading...
18973

+
P2.01 - Advanced NSCLC
- 09:00 - 16:00
- 10/17/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Advanced NSCLC
- 23139
  
  +
  
  P2.01-016 - Prognostic Impact of a New Score Using Neutrophil-To-Lymphocyte Ratios in the Serum and Malignant Pleural Effusion in Lung Cancer Patients
  
  09:00 - 09:00 | Presenter: Hae-Seong Nam | Author(s): C. Kim, D. Kim, J.H. Lim, S. Jeon, J.S. Kim, Y.S. Lee, J.H. Cho, J. Ryu
  Abstract
  
  Loading...
- 23158
  
  +
  
  P2.01-035 - Phase II Study: Weekly Docetaxel as First Line Chemotherapy for Elderly Patients with Squamous-Cell Non-Small-Cell Lung Cancer
  
  09:00 - 09:00 | Presenter: Kyung Ho Kang | Author(s): Sung Yong Lee, J.H. Choi, S.M. Chung, J.Y. Oh, Y.S. Lee, K.H. Min, G.Y. Hur, J.J. Shim, H.K. Lee
  Abstract
  
  Loading...
- 23187
  
  +
  
  P2.01-064 - Co-Existing Mutations and Their Clinical Implications in Non-Small Cell Lung Cancer: Korean Lung Cancer Consortium (KLCC-13-01)
  
  09:00 - 09:00 | Presenter: Bo Mi Ku | Author(s): N.L. Lee, M.S. Kim, Jong-Mu Sun, S. Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn
  Abstract
  
  Loading...
18972

+
P2.02 - Biology/Pathology
- 09:30 - 16:00
- 10/17/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Biology/Pathology
- 23209
  
  +
  
  P2.02-011 - Clinical and Molecular Features of Lung Cancers with Increased FGFR1 mRNA and/or Gene Copy Number
  
  09:30 - 09:30 | Presenter: Terry L. Ng | Author(s): Hui Yu, E. York, S. Leedy, D. Gao, L. Heasley, Fred R. Hirsch, D. Ross Camidge
  Abstract
  
  Loading...
20167

+
P2.03 - Chemotherapy/Targeted Therapy
- 09:30 - 16:00
- 10/17/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Chemotherapy/Targeted Therapy
- 23293
  
  +
  
  P2.03-022 - Impact of EGFR Mutation on Clinical Outcome of Nintedanib plus Docetaxel in Previously Treated Non- Small Cell Lung Cancer (NSCLC)
  
  09:30 - 09:30 | Presenter: Jin-Hyoung Kang | Author(s): S. Hong, H.J. Ahn, K..H. Kim, S.S. Lee, Y.G. Lee, Y.J. Yuh, P. I Cheon, Y.S. Chae, T.W. Jang
  Abstract
  
  Loading...
- 23301
  
  +
  
  P2.03-030 - Cumulative Smoking Dose Affects the Clinical Outcomes of EGFR-Mutated Lung Adenocarcinoma Patients Treated with EGFR-TKIs
  
  09:30 - 09:30 | Presenter: In Ae Kim | Author(s): H.J. Kim, J.S. Lee, K.Y. Lee
  Abstract
  
  Loading...
20171

+
P2.07 - Immunology and Immunotherapy
- 09:30 - 16:00
- 10/17/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Immunology and Immunotherapy
- 23400
  
  +
  
  P2.07-025 - Increased Antitumor Response to Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer
  
  09:30 - 09:30 | Presenter: Song Ee Park | Author(s): Y. Kim, H.K. Kim, H. Lee, J.H. Cho, S.W. Lim, S. Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn, Jong-Mu Sun
  Abstract
  
  Loading...

Session Information

WCLC 2017

18th World Conference on Lung Cancer

Enter Virtual Meeting Access Code

+

P1.02 - Biology/Pathology

+

P1.02-003 - Prevention of Adriamycin-induced Cardiac Damage by NAD-ModulationPrevention of Adriamycin-induced Cardiac Damage by NAD-Modulation

+

P1.02-024 - Correlation of Maximal Tumor Diameter between Pathology Specimen and CT in Nonsmall Cell Lung Cancer: A Pilot Study

+

P1.05 - Early Stage NSCLC

+

P1.05-014 - Efficacy of Adjuvant Chemotherapy for Completely Resected Stage IB Non-Small Cell Lung Cancer

+

P1.08 - Locally Advanced NSCLC

+

P1.08-004 - Adjuvant Chemoradiotherapy vs. Chemotherapy for Completely Resected Unsuspected N2-Positive Non-Small Cell Lung Cancer

+

P1.13 - Radiology/Staging/Screening

+

P1.13-006 - The Value of F-18 FDG PET/CT-guided EBUS-TBNA in Nodal Staging of NSCLC.

+

OA 03 - Mediastinal and Esophageal Tumor: Insight and New Treatment

+

OA 03.04 - A Phase II Study of Pembrolizumab for Patients with Refractory or Relapsed Thymic Epithelial Tumor

+

OA 05 - Next Generation TKI

+

OA 05.02 - Osimertinib vs SoC EGFR-TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC (FLAURA): Plasma ctDNA Analysis

+

P2.01 - Advanced NSCLC

+

P2.01-016 - Prognostic Impact of a New Score Using Neutrophil-To-Lymphocyte Ratios in the Serum and Malignant Pleural Effusion in Lung Cancer Patients

+

P2.01-035 - Phase II Study: Weekly Docetaxel as First Line Chemotherapy for Elderly Patients with Squamous-Cell Non-Small-Cell Lung Cancer

+

P2.01-064 - Co-Existing Mutations and Their Clinical Implications in Non-Small Cell Lung Cancer: Korean Lung Cancer Consortium (KLCC-13-01)

+

P2.02 - Biology/Pathology

+

P2.02-011 - Clinical and Molecular Features of Lung Cancers with Increased FGFR1 mRNA and/or Gene Copy Number

+

P2.03 - Chemotherapy/Targeted Therapy

+

P2.03-022 - Impact of EGFR Mutation on Clinical Outcome of Nintedanib plus Docetaxel in Previously Treated Non- Small Cell Lung Cancer (NSCLC)

+

P2.03-030 - Cumulative Smoking Dose Affects the Clinical Outcomes of EGFR-Mutated Lung Adenocarcinoma Patients Treated with EGFR-TKIs

+

P2.07 - Immunology and Immunotherapy

+

P2.07-025 - Increased Antitumor Response to Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer

Stay Connected